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The aims of this study are: 
 Present a review of Epidermolysis Bullosa’s research, 
understanding the rare disease’s context.  
 Expose the protein, gene and cell therapies trials published, in 
order to discuss their treatment potential in humans.  
 Understand the tissue regeneration and purpose a future strategy 
through 3D skin bioprinting.   
 Search articles in PubMed database published between 2008 and 
2015 using the following terms: Epidermolysis Bullosa, rare diseases, 
orphan drugs, EB treatment, gene therapy for EB, cell therapy for EB, 
skin regeneration.  
 Search scientific literature in conferences, Gene and Cell Therapy 
books and courses related with rare diseases.  
 Consult reference web pages like CIBERER, EURORDIS, 
ORPHANET, UpToDate and GeneGraft.   
 Contact to Marcela del Rio, principal investigator for Epidermolysis 
Bullosa in CIBERER, and contact the association DEBRA in Spain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Epidermolysis Bullosa is a complex rare disease with many clinical forms, that challenges the biomedical investigation. 
The patient’s associations role, like DEBRA, are very important as a support to these and for investing in research. It’s also important to have the world biobank where many EB samples can 
facilitate the study.  
The main treatment for EB is symptomatic and dealt with the care of wounds and blisters on a daily basis, as well as performing a small prophylaxis avoiding friction that can cause damage 
to the patient. Despite this, current research in this area is very active, which tries to develop new treatment strategies based on the therapies combination, and bioengineering. 
Although the best potential therapy would be gene therapy, currently there are more developed cell therapies, especially using mesenchymal stem cells and reversed epidermal stem cells. 
A possible hopeful future strategy could be the skin creation through 3D bioprinters. 
The main limitation in EB treatment’s research is the health care cost (orphan drugs), as this is a minority disease that affects relatively few patients. This is the principal weakness in 
biomedical research as it also involves an issue of ethics. 
Cell Therapy 
Protein Therapy 
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Types 
Main Gene and Protein 
affected 
Features 
EB simplex  
(92%) 
 
KRT5 (keratin 5) 
KRT14 (keratin 14) 
Intraepidermal shapes (basal 
keratinocytes); Autosomal recessive or 
dominant 
Junctional EB  
(1%)  
 
LAMB3 (laminin 322) 
COL17A1 (collagen XVII) 
 
Anchoring fibrils (basal membrane); 
Autosomal recessive 
Dystrophic 
EB (5%) 
 
COL7A1 (collagen VII) 
Dermal shapes; Autosomal recessive 
or dominant. Severe 
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Local  Therapy 
• Intradermal injection 
• Skin grafts 
Systemic Therapy 
• Intravenous injection 
• Intraarterial injection 
Skin healing effects Healing effects on skin and 
mucosa 
Figure 2. Combined therapies for EB [Adapted from Tolar et al, 2015] 
Systemic infusion of recombinant absent protein. 
There are good results in pre-clinical trials with 
murine model, that suggest it could be a possible 
treatment in humans.  
        1) Intradermal injections 
        2) Intravenous injections   
Both are safety/effective systems that improve the EB 
phenotype accelerating wound healing. However, 
necessary dosing levels has yet to be determined. 
Healthy skin EB skin 
Epidermolysis Bullosa (EB) is a group of genetically transmitted and chronic skin disorders 
without effective treatment. It affects 1 in 17.000 children and is characterized by 
spontaneous mucocutaneous blistering and ulcers caused by minor trauma.  
About 18 genes have been identified to be involved in EB’s etiology, encoding structural 
proteins and adhesive molecules of the epidermal basement membrane, resulting in over a 
thousand mutations that may occur de novo or follow a pattern autosomal dominant or 
recessive inheritance. The level of expression of these genes in the different skin layers and 
different types of mutations explain the phenotypic variability of the disease. So the 
pathophysiology consists in abnormal separation of skin layers due to genetic defects that 
alter one or more essential dermo-epidermal junction molecules.  
There are three EB classic types (Table 1) which are differentiated by type of injury, 
histological characteristics, anatomical location, pattern of inheritance and gene mutation. 
The clinical presentation varies according to the type of disease. 
Figure 1. Structures of healthy and EB skin and molecules affected with blister formation. It is shown 
also an immunofluorescence  where collagen VII is marked in green  -normal skin- [Tolar et al, 2015] 
Table 1. Classic types of EB  
Innovative technique in regenerative medicine to treat 
dermatological diseases like EB through skin creation with 3D 
bioprinter. 
Scanner area and 
depth of the ulcer 
Figure 11. Skin creation process through 3D bioprinter 
[Adapted from www.3ders.org] 
Most promising therapies based on keratinocytes and epidermal stem cells can correct due to the insertion 
of a normal copy of the gene (encouraging results both in vivo and ex vivo). The research develops slowly 
because of the delivery vector (must be secure without causing immunogenicity), although it is believed it 
could be one of the best strategies for the future.  
Gene therapy methods: viral vectors, non viral vectors, zinc finger nucleases and TALENs, and siRNA. 
Figure 10. Ex vivo therapy. From patient’s mutated cells the gene correction is 
performed in the laboratory by entering the target gene through a vector and 
transplanted the corrected skin layer. [Adapted from conference Dr Robinson from DEBRA 
International] 
Figure 9. Images above: RDEB patient skin, fragile 
and non expressed collagen VII. Images below: 
Genetically corrected skin in laboratory with 
collagen VII expression. [Conference Marcela del Rio, 
2015] 
1. Allogenic Fibroblasts. Intradermal 
injection leads to increased C7 expression in 
dermal-epidermal junction (ulcer’s healing). 
Limitations: 
 C7 expression just for 28 days 
 Multiple local injections (effectiveness?) 
2. Allogenic Blood and Bone Marrow 
Cells. Increased fully functional lympho-
haemopoietic system which develops 
different cellular shapes. 
 Cellular capacity to secrete C7 in lesions 
 Long-term heal internal lesions  
 Security and effectiveness? 
3. Mesenquimal Stem Cells. Currently the most important therapy for ulcer’s healing. Cells 
can be isolated from bone marrow or adipose tissue and their potential characteristics are: 
 Antiinflammatory 
 Source of C7 
 Pro-angiogenic  
 Antimicrobial 
 
4.Natural Therapy: revertant mosaicism. 
Second-site somatic mutation that corrects 
the inherited one and produce a normal patch 
skin (auto-corrected cells). 
5. Induced Pluripotent Stem Cells 
(iPSC). Dedifferentiated keratinocytes and 
fibroblasts to create genetically corrected 
cells. 
Figure 3. Two possible administration: bioengineered 
skin (top) and intradermal injections (bottom)  
[Adapted from Robinson, 2010] 
Figure 4. Normal 
collagen VII 
secreted by donor 
cells and potentially 
keratinocytes 
[Adapted from Tolar 
et al, 2013] 
Figure 6. MSC cell 
therapy process. 
Transplanted MSC 
remain in dermal layer 
[Created by author] 
Figure 7. Patch’s cells are used for bioengineered skin  
[Adapted from M. Del Rio, 2015]   Figure 8. Cellular reprogramming [Adapted from Robinson, 2010] 
Figure 5. Increased C7 
expression and clinical benefit 
after transplantation 
[Adapted from Tolar et al, 2013] 
